PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2017Clinical Epidemiology15 citationsOpen Access

Clinical validation of immunoglobulin A nephropathy diagnosis in Swedish biopsy registers

View Full Paper
SJSimon JarrickÖrebro UniversitySLSigrid LundbergKarolinska University HospitalAWAdina WelanderKarolinska University Hospital

Key Points

Key points are not available for this paper at this time.

Abstract

Aims: The aims of this study were to validate the diagnosis of IgA nephropathy (IgAN) in Swedish biopsy registers against patient charts and to describe the clinical characteristics of patients with a biopsy indicating IgAN. Methods: This is a population-based cohort study. Out of 4,069 individuals with a renal biopsy consistent with IgAN (biopsies performed in 1974–2011), this study reviewed patient charts of a random subset of 127 individuals. Clinical and biopsy characteristics at the time of biopsy were evaluated, and positive predictive values (PPV) were calculated with 95% confidence intervals (CI). Results: Out of 127 individuals with a renal biopsy consistent with IgAN, 121 had a likely or confirmed clinical diagnosis of IgAN, primary or secondary to Henoch–Schönlein purpura, yielding a PPV of 95% (95% CI =92%–99%). The median age at biopsy was 39 years (range: 4–79 years); seven patients (6%) were Conclusion: A histologic diagnosis of IgAN has a high PPV for a diagnosis of IgAN confirmed by review of patient charts. Keywords: general population-based, histopathology, IgA nephropathy, kidney, renal disease, validation studies Corrigendum for this paper has been published

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jarrick et al. (2017) studied this question.

synapsesocial.com/papers/6a106f96b6f5ee040160aad4https://doi.org/10.2147/clep.s118730
Ask AI
Helpful
Bookmark
Share
View Full Paper